Liposomes are small, artificial and lipid-based bilayered spherical vesicles, which are created spontaneously by hydrated phospholipids. Owing to their ability to encapsulate bioactive hydrophilic, amphipathic, and lipophilic molecules, liposomes are extensively used as efficient delivery systems for antigens or drugs.

The global liposome manufacturing market size is estimated to reach USD 2.34 billion by 2035, growing at a CAGR of 9.7% during the forecast period.

Over the years, several companies involved in the development of liposomes have made significant efforts in conducting clinical trials for evaluating the efficacy of liposome-based therapeutics, for the treatment of various oncological disorders.

Gene switches have garnered significant attention from drug developers owing to their ability to control the activity of genetically modified cell products in vivo

The global gene switch market size is estimated to grow from USD 795 million in 2025 to USD 2,478 million by 2035, representing a CAGR of 12.03% during the forecast period till 2035.

Driven by numerous developmental breakthroughs and encouraging study results demonstrating the vast potential of adoptive cell therapies (ACT), including CAR-T cell therapies, TCR therapies, TILs and natural killer cell therapies, in the treatment of various complex disorders, this therapeutic modality has garnered considerable attention from the players engaged in the pharmaceutical industry.